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Abstract
Context: Anxiety disorders are common, with a lifetime prevalence of 20% in the U.S., and are responsible for substantial
burdens of disability, missed work days and health care utilization. To date, no causal genetic variants have been identified
for anxiety, anxiety disorders, or related traits.
Objective: To investigate whether a phobic anxiety symptom score was associated with 3 alternative polygenic risk scores,
derived from external genome-wide association studies of anxiety, an internally estimated agnostic polygenic score, or
previously identified candidate genes.
Design: Longitudinal follow-up study. Using linear and logistic regression we investigated whether phobic anxiety was
associated with polygenic risk scores derived from internal, leave-one out genome-wide association studies, from 31
candidate genes, and from out-of-sample genome-wide association weights previously shown to predict depression and
anxiety in another cohort.
Setting and Participants: Study participants (n=11,127) were individuals from the Nurses’ Health Study and Health
Professionals Follow-up Study.
Main Outcome Measure: Anxiety symptoms were assessed via the 8-item phobic anxiety scale of the Crown Crisp Index at
two time points, from which a continuous phenotype score was derived.
Results: We found no genome-wide significant associations with phobic anxiety. Phobic anxiety was also not associated
with a polygenic risk score derived from the genome-wide association study beta weights using liberal p-value thresholds;
with a previously published genome-wide polygenic score; or with a candidate gene risk score based on 31 genes
previously hypothesized to predict anxiety.
Conclusion: There is a substantial gap between twin-study heritability estimates of anxiety disorders ranging between 20–
40% and heritability explained by genome-wide association results. New approaches such as improved genome
imputations, application of gene expression and biological pathways information, and incorporating social or
environmental modifiers of genetic risks may be necessary to identify significant genetic predictors of anxiety.
Citation: Walter S, Glymour MM, Koenen K, Liang L, Tchetgen Tchetgen EJ, et al. (2013) Performance of Polygenic Scores for Predicting Phobic Anxiety. PLoS
ONE 8(11): e80326. doi:10.1371/journal.pone.0080326
Editor: Monica Uddin, Wayne State University, United States of America
Received February 5, 2013; Accepted September 24, 2013; Published November 20, 2013
Copyright:  2013 Walter et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors gratefully acknowledge funding from NIH/NIMH (MH092707-01). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript. Stefan Walter had full access to all of the data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: swalter@hsph.harvard.edu
Introduction
Anxiety disorders, the most commonly occurring psychiatric
disorders in the United States, account for a substantial burden of
disability, increased health care utilization, and high absenteeism
from work [1,2]. Twin studies typically suggest heritability of
anxiety disorders between 20–40% [3,4], and up to 50–55% for
traits proposed as endophenotypes (e.g., neuroticism, behavioral
inhibition) [5]. However, these twin study heritability estimates do
not reveal anything about the genetic architecture of anxiety. For
example, the heritability could be largely attributable to a small
number of high risk alleles or a large number of low risk alleles
[4,6,7,8,9].
To date, no causal genetic variants have been identified for
anxiety, anxiety disorders, or related traits. Only a handful of small
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e80326(n’s range from 200–2,235) genome-wide association studies
(GWAS) of anxiety disorders and neuroticism have been published
[10,11,12,13], and efforts to replicate findings from these studies
have failed [12,14,15,16]. Furthermore, findings from candidate
gene studies have not been confirmed by GWAS. It may be that
publication bias and the ‘‘winner’s curse’’ lead to overly optimistic
effect estimates in the discovery stage of gene-disease association
studies. GWAS and candidate gene studies have considered
multiple forms of anxiety, including panic disorder, phobic anxiety
and neuroticism. However, thus far no conclusive evidence has
linked a specific genetic marker with any form of anxiety, nor has
evidence suggested that any one form of anxiety disorder has a
stronger genetic basis than any other. Several hypotheses for the
absence of confirmed loci have been posited, including the
possibility that the heritability of anxiety is attributable to a large
number of alleles each with effect sizes too small to detect in
GWAS [17]. Evidence supporting a polygenic basis of anxiety was
reported in a recent paper by Demirkan et al., in which ,2% of
anxiety was predicted in independent samples using genome-wide
polygenic risk scores derived from a GWAS of depression [18].
Genome-wide, pathway non-specific, or ‘‘hypothesis-free’’,
polygenic risk scores are constructed based on the associations
for a large number of alleles meeting nominal p-value significance
criteria, even while assuming that many or even most of these
alleles are false positives. While a typical GWAS tests millions of
single nucleotide polymorphisms (SNPs) for association with the
phenotype of interest and applies very conservative alpha criteria
(e.g.,5 610
28) for statistical significance, polygenic risk scores
incorporate information from SNPs that are not genome-wide
significant. If polygenic risk scores explain substantial variance in
anxiety phenotypes, it would provide indirect evidence for the
common disease – common variant hypothesis; common alleles,
each with a small effect on disease, largely explain the heritability
of complex polygenic diseases [18,19].
To test the hypothesis that heritability of phobic anxiety can be
explained by common SNPs, we considered the variation in
phobic anxiety that can be explained using GWAS-derived
polygenic risk scores in genotyped sub-samples of women from
the Nurses’ Health Study (NHS) and men from the Health
Professionals Follow-up Study (HPFS). We also assessed a
polygenic risk score based on 31 candidate genes identified a
priori from published literature. Finally, we attempted to replicate
the finding from Demirkan and colleagues by creating a polygenic
score (developed from the GWAS of depression in their sample)
using weights identical to those in the original study [18].
Materials and Methods
Ethics Statement
The NHS and HPFS were approved by the Human Subjects
Committee of Brigham and Women’s Hospital, Boston, MA. All
participants in this study provided written informed consent.
Population
All data are drawn from 7 nested case-control GWAS within the
NHS and HPFS cohorts.
Nurses’ Health Study (NHS). The NHS was established in
1976 when 121,700 female registered nurses aged 30–55 years and
residing in 11 large U.S. states completed a mailed questionnaire
on medical history and lifestyle characteristics [20]. Participants
have been followed with repeated questionnaires on lifestyle and
health every 2 years. Blood was collected from 32,826 participants
between 1989 and 1990. DNA was extracted from white blood
cells using the QIAmp
TM (QIAGEN Inc., Chatsworth, CA) blood
protocol and all samples were processed in the same laboratory.
Genome-wide scans were obtained from 4 independent GWAS of
the cohort, initially designed to examine type 2 diabetes (T2D),
coronary heart disease (CHD), breast cancer (BrCa) and kidney
stone (KS) disease. Both cases and controls were included in the
current analyses because the link between any given genotype or
gene score and anxiety was expected to be independent of disease
status. For the NHS T2D GWAS, 3286 participants were
genotyped with controls defined as women free of diabetes at
the time of diagnosis of the case, and matched on year of birth,
month of blood collection, and fasting status. These matched-pairs
were subsequently broken because not all subjects gave informed
consent to post their data on dbGaP. For the NHS CHD set 1146
participants were included. CHD cases were matched on age,
smoking, and month of blood draw to controls (1:2) randomly
selected from women who provided blood samples and did not
have CHD on the date of diagnosis of the case. For the NHS BrCa
study (n=2287) cases and controls were limited to post-
menopausal women. Controls were women without breast cancer
and matched 1:1 with cases by age and post-menopausal hormone
use at blood draw. In the NHS KS study (n=504), cases were
women with a history of kidney stones, and controls randomly
selected from among women with no history of cancer or
cardiovascular disease and who met age eligibility requirements
for every case (1:0.5).
Considering quality control (QC) and available information on
phobic anxiety a total of 7002 genotyped participants were
available from NHS (NHS T2D=3105, NHS CHD=1133, NHS
BrCa=2274, NHS KS=490).
Health Professionals Follow-up Study (HPFS). The HPFS
was initiated in 1986 when 51,529 male health professionals
between ages 40 and 75 years and residing in the U.S. completed a
questionnaire on lifestyle and medical history. Participants have
been followed with repeated questionnaires on lifestyle and health
every 2 years.
Between 1993 and 1996, a blood sample was requested from all
active participants and collected from 18,225 men [21]. DNA was
extracted from white blood cells using the QIAmp
TM (QIAGEN
Inc., Chatsworth, CA) blood protocol; all samples were processed
in the same laboratory. Genome-wide scans were obtained from 3
independent GWAS of the cohort, initially designed to examine
T2D, CHD, and KS disease. Both cases and controls were
included for analysis. In the HPFS T2D (n=2487), CHD
(n=1313), and KS (n=553) participants were genotyped follow-
ing the same design and method for selecting cases and controls as
used in the NHS parallel sub-studies. In total, 4125 HPFS
participants (T2D n=2279, CHD n=1294, KS n=552) were
included, after restrictions based on QC and missing information
on phobic anxiety.
Genotyping and Imputation
Exact genotyping, QC, and imputation protocols varied by
sample set (Tables S1 and S2). DNA samples that did not meet at
least 90% (NHS) or 95%(HPFS) completion threshold and SNPs
with low call rates ,90% (NHS) or #95% (HPFS) were dropped.
Principal components analyses were conducted to exclude self-
reported white individuals that had substantial similarity to non-
European reference samples [22]. Each study imputed up to 2.5
million autosomal SNPs with NCBI build 36 of Phase II HapMap
CEU data (release 22) as the reference panel using MACH
[11,19]. Imputation results summarized as allele dosage were used
for analysis. dbGaP accession numbers for the publicly funded
genotyping are: NHS T2D (phs000091.v2.p1), NHS BrCa
(phs000147.v1.p1), , HPFS T2D (phs000091.v2.p1), NHS/HPFS
Polygenic Scores for Phobic Anxiety
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supported by Merck and are not in dbGaP.
Phenotype
Anxiety symptoms were assessed using the phobic anxiety scale
of the Crown Crisp Experimental Index (CCI). The scale includes
8 questions about fear of crowds, heights, enclosed spaces, and
going out alone, and worrying; items have two or three response
options. Items with 3 response options were scored as no (0),
moderate (1), or high (2); symptom level items with 2 response
options were coded as no (0), or high (2) symptom level. We
summed across items, resulting in an overall score ranging from 0
to 16 with higher scores indicating higher levels of phobic anxiety.
For those with missing items, the total score was divided by the
fraction of questions answered and then rounded to the nearest
whole number, so the possible range of total scores was consistent
across all individuals.
This scale discriminates individuals with diagnosable anxiety
disorders from healthy individuals, correlates reasonably with
other measures from the Middlesex Hospital Questionnaire (free-
floating anxiety r=0.48, obsessional r=0.45, somatic
r=0.42,depressive r=0.27) [23], has high intra-class correlation
in monozygotic twins (0.60) and high heritability (0.64) [24], and is
associated with heart disease in both men and women [25,26,27].
To reduce the impact of measurement error or short term
fluctuations in CCI, we averaged two CCI assessments (NHS:
1988, 2004; HPFS: 1988, 2000). For cohort members who
provided only one CCI score, we used that measure. The
distribution of the CCI score stratified by case-control status is
reported in Table S3.
Analyses
Genome Wide Association Analysis. Genome-wide associ-
ation analyses were conducted separately for each of the 7 sample
sets. We related dosage genotype across 2.5 million SNPs to the
continuous phobic anxiety score using linear regression under an
additive genetic model. Even though we analyzed unrelated
individuals, we additionally adjusted for the top three or four
eigenvectors to address residual population stratification. Fixed-
effects meta-analysis with GWAMA was used to combine the
results of the 7 cohorts [28,29].
Agnostic (Hypothesis-Free) Genome Wide Polygenic Risk
Score Profile. To evaluate the predictive value of a combina-
tion of SNPs across studies, the meta-analyzed results from the
genome-wide association analyses were restricted to 1.54 million
SNPs imputed with R
2.95% across all study samples and further
restricted to a set of 94,657 independent SNPs using the PLINK
pruning procedure. Briefly, specifying a window of 200 SNPs, the
corresponding LD between each pair of SNPs was calculated and
one of the pair of SNPs was removed if the LD was greater than
0.25. Subsequently the window was shifted forward by 5 SNPs and
the procedure repeated.
We estimated polygenic risk scores following prior similar work
[18,19]. This method entails 3 steps: 1) estimating beta weights for
each SNP based on a GWAS in a discovery sample; 2) restricting
to SNPs with p-values below a pre-specified threshold (we
considered alternative thresholds ranging from 0.00001 to 0.5);
3) calculating a polygenic risk score for each individual in a target
sample as the sum of risk alleles from the previously selected list of
SNPs, with each SNP weighted by the beta estimate from the
discovery sample.
Genome-wide data for both NHS and HPFS were collected in
separate nested case control studies, resulting in 7 distinct samples
in our analyses. For each individual in each sample, the risk score
was calculated using the SNPs and beta weights derived from the
other 6 samples as the meta-analyzed discovery set. The risk score
for predicting phobic anxiety was calculated by multiplying the
estimated beta weight by the number of risk alleles at each SNP (0,
1, 2) and summing across all SNPs in the SNP set defined by the p-
value threshold from the discovery set.
We then used linear regression to quantify the association
between the polygenic risk score and the phobic anxiety
phenotype in each target sample. After iterating across all seven
studies, always leaving out one study as the target sample, the
resulting variances explained (R
2) from the scoring procedure were
meta-analyzed by weighting with the sample size of each target set.
Replication of Previously Established Polygenic Risk
Score. Demirkan and colleagues previously used the above
procedure to develop a polygenic risk score for major depressive
disorder as assessed by the Composite International Diagnostic
Interview [30]. They tested the score in Rotterdam Study
participants (age 55 years and older) using a case-control design
with 222 anxiety disorder cases (including generalized anxiety
disorder, panic disorder, agoraphobia, social phobia and specific
phobia, assessed with Munich Composite International Diagnostic
Interview (M-CIDI). In analyses comparing these cases to 290
controls with no M-CIDI disorder and a Hospital Anxiety and
Depression-Anxiety score of zero, the polygenic score explained
approximately 2% of the variance. Demirkan and colleagues
(personal communication) provided the precise beta weights (log
odds) and p-values used in this analysis to facilitate creation of the
polygenic score and replication in our cohorts. To be consistent
with the Demirkan analysis which dichotomized anxiety, we
defined a dichotomous phobic anxiety phenotype:scoring 4+ on
the phobic anxiety scale at either assessment (Table 1), chosen
based on prior work [25]. We assessed the association between the
score derived by Dermirkan and colleagues and our dichotomous
phenotype using logistic regression R
2.
Candidate Gene Risk Score. In addition to using GWAS to
identify likely candidate SNPs, we selected the following 31
candidates genes identified in prior literature [5,6,10,31,32].
ADORA2A, ADRB1, ANO2, ARRDC4, BDNF, CALCOCO1, CCK,
CCKBR, CLU, COMT, CRH, CRHR1, GAD1, GPC6, HTR1A,
HTR2A, HTR3A, MAPT, MDGA2, NKAIN2, OXT, PDE4D, PKP1,
PLEKHG1, PLXNA2, RGS2, SDK2, SLC1A1, SLC6A3, SLC6A4,
TPH2. These candidate genes were matched to the imputed SNPs
by chromosomal position +/220 kb using the USCS genome
browser via http://genome.ucsc.edu/. The 7984 SNPs that
matched to the genes were restricted to those that were well
imputed with R
2.95% across all studies (n=4887) and further
pruned to 370 independent SNPs with the same methodology as
described above with each gene being represented by at least one
SNP. A candidate gene risk score was derived using these
candidate gene SNPs with weights derived from the meta-analysis
described above and the same p-value thresholds used for testing
the GWAS-derived polygenic score.
Proportion of Phenotypic Variance Explained. To ad-
dress the capacity of the common SNPs genotyped on the different
platforms to explain phobic anxiety, we estimated the phenotypic
variance explained in each case-control sample following the
approach suggested by Yang et al. [33] using the standard
Genome-wide Complex Trait Analysis (GCTA) protocol. We
present the average of the GCTA estimates, calculated with
weighting by sample size; these results should be interpreted
cautiously because they combine GCTA information from
different platforms.
Polygenic Scores for Phobic Anxiety
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Of the 11,127 participants with information on anxiety and
genotype, 63% were female (Table 1). The first and second
measurement of the CCI phobic anxiety index were correlated at
Pearson r=0.59.
In the genome-wide meta-analysis of all seven data sets
(Figure 1), no SNP reached genome-wide significance (i.e.
significant at p,5610
28) but 10 independent signals passed the
suggestive threshold of p,1610
25 (Table 2). The SNP with the
strongest association was rs4911015 (p=7.38610
27) on chromo-
some 13.
In meta-analyzed results with independent target samples, the
derived agnostic polygenic risk score was never associated with
phobic anxiety at nominally significant (p,.05) thresholds for any
of the tests. The variance explained (Table 3) was negligible
(maximum 0.01%) regardless of which p-value threshold was used
to select SNPs for inclusion in the risk score calculation. These
results were consistent across several modifications of the inclusion
criteria, including relaxing the restriction of 95% imputation
Table 1. Descriptive statistics of 11127 study participants.
NHS (7002 females) HPFS (4125 males)
Mean/Frequency Standard Deviation/(%) Mean/Frequency Standard Deviation/(%)
Age at blood draw (yrs) 57.8 6.8 62.2 9.2
1
st Measure of Phobic Anxiety* 2.8 2.2 1.9 1.9
2
nd Measure of Phobic Anxiety** 2.8 2.4 1.9 1.9
Mean of 1
st and 2
nd Measurement of Phobic Anxiety 2.8 2.1 1.9 1.7
Ever Phobic Anxiety? (1
st or 2
nd Measurement $4) 2937 42.0 1068 25.9
*Missing Information: NHS=175, 5.1% of participants with item non-response, 0.1% with item non-response .2 out of 8 items; HPFS=328, 1.1% of participants with
item nonresponse, 0.1% with item non-response .2 out of 8 items.
**Missing Information: NHS=1093 (726 due to death) 4.1% of participants with item non-response, 0.2% with item non-response .2 out of 8 items; HPFS=479 (294
due to death), 5.1% of participants with item non-response, 0.2% with item non-response .2 out of 8 items.
doi:10.1371/journal.pone.0080326.t001
Figure 1. Genome wide association plot (Manhattan plot), phobic anxiety in the Nurses’ Health Study and the Health Professionals
Follow-up Study (n=11,127).
doi:10.1371/journal.pone.0080326.g001
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risk scores, or additionally adjusting for case status in the respective
case-control studies (results not shown).
We next applied the Demirkan weights to construct the
depression-derived polygenic risk score in our sample. This score
did not predict the dichotomized phobic anxiety phenotype in our
sample, even with weights and p-value thresholds identical to those
applied by Demirkan et al. (Table 3); nor did it predict the
continuous phobic anxiety score or a more extreme dichotomous
outcome using the highest scoring decile of the CCI distribution as
the cut-off value (results not shown). To facilitate comparison with
the results derived from the internal score and to address concerns
regarding the combined use of cases and controls in this analysis,
we provide additional regression results showing no association
between the depression-derived polygenic risk score and contin-
uous the continuous phobic anxiety score in Table S4.
The candidate gene risk score, based on SNPs in local
neighborhoods of 31 candidate genes, was also unrelated to the
phobic anxiety phenotype (Table 3).
Exploratory GCTA analyses revealed an estimated heritability
explained by all common SNPs ranging from 0% for 31%,
averaging to 17% across the 7 different study samples (Table S5).
We have developed a set of policies and guidelines to
accommodate independent review upon request.
Discussion
In a GWAS of a large sample of men and women of European
descent, we found no genome-wide significant associations with
phobic anxiety. Phobic anxiety was also not associated with a
polygenic risk score derived from the GWAS beta weights using
liberal p-value thresholds; with a previously published genome-
wide polygenic score; or with a candidate gene risk score based on
31 genes previously hypothesized to predict anxiety.
Genome-wide, pathway non-specific, hypothesis-free polygenic
risk scores such as those used in this study potentially capture small
elevations in risk associated with SNPs that would not meet
conventional genome-wide significance thresholds. This approach
may thus ameliorate the ‘‘false negative’’ problem in typical
GWAS, but this advantage comes at the costs of adding noise to
the prediction because many ‘‘false positives’’ are included in the
score calculation. To address this inflation of ‘‘false positives’’ in
the score we tested a polygenic risk score restricted to SNPs located
in the neighborhood of candidate genes incorporating prior
knowledge about the genetics and biology of anxiety.
Genome-wide polygenic risk scores have been informative for
traits like schizophrenia, bipolar disorder, coronary heart disease
and type II diabetes [19,34] though less informative for cancer
[35]. When substantial phenotypic variance can be explained by
genome-wide polygenic risk scores, despite few or no individual
SNPs that meet the genome-wide significance threshold, it
supports the common disease-common variant hypothesis. Such
a finding would suggest genetic risk is distributed across many
independent loci with small effects.
Our null findings cannot be considered to disconfirm the
common disease common variant hypothesis for phobic anxiety,
however. Common genetic variants with very small effects may
exist but be undetectable in this analysis because of lack of
statistical power. This study had 80% power to detect a single SNP
associated with 0.16 SD unit change of the continuous anxiety
phenotype if such a SNP had a minor allele frequency of 5%;
equivalently, we had power to detect a single SNP explaining
0.34% of the variance. Assuming a 20% chip heritability as
suggested by GCTA (Table S5) and prior twin studies, an average
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individuals, the power of the polygenic risk score in our analysis
was 80% to detect a nominally significant association if the genetic
risk was distributed across 1% of the risk markers considered [36].
Even if the genetic risk was distributed across all 94 657 SNPs
considered in the polygenic risk score, our analyses still had 75%
power to detect an association at a p-value threshold of 0.5 (Table
S6).
There are several possible explanations for our inability to
replicate the prior association between a genome-wide polygenic
risk score and anxiety [18]. Anxiety is a defining feature of several
related disorders. Though specific anxiety symptoms are common
to most of the disorders, variation in heritability estimates may be
partly attributed to differences across anxiety disorders. For
example, panic disorders, as defined by repeated and unexpected
panic attacks, can be distinguished phenotypically from phobic
disorders, exemplified by the fear of developing panic-like
symptoms and avoidance behavior with respect to specific object
or situation [6]. The genetics of phobic anxiety, the phenotype in
our study, may differ from the genetics of the HADS-A,
generalized anxiety, measure used in Demirkan et al. Nonetheless,
because all anxiety disorders aggregate in families attributed to
shared genetic risk [3], and because data from a population-based
twin registry suggests that the genetic components of anxiety are
shared across different anxiety disorders [4], we would have
expected at least a partial replication of their findings [5,6,32]. It is
also possible that, given the divergence of the demographic and
social conditions of the populations in the two studies, the finding
in an older Dutch community sample do not generalize to our
occupationally-based U.S. cohorts.
Nonetheless our results are consistent with most research on
anxiety genetics. Of three GWAS of neuroticism [11,12,13,16], an
endophenotype of anxiety, none of the findings have been
replicated. Likewise, candidate genes studies have not established
replicable risk genes [17]. Together, these results suggest that
understanding the genetics of anxiety may require very large
sample sizes and also a broader analytic approach. It seems
increasingly likely that heritability is not conferred mainly through
SNPs but through other genetic or epigenetic modifications, such
as deletions, inversions, translocation and differential gene
regulation as recent findings regarding anxiety and related mental
disorders suggest that miRNA, rare alleles, copy number
variations, and epigenetic modifications may play key roles in
shaping the phenotypes [14,15,37,38,39,40].
Substantial gene-environment interactions may also obscure the
relevant genetic risk factors, and inflate heritability estimates from
twin studies. If genotype-phenotype associations are heterogeneous
across environmental contexts, the associations may be absent or
diluted in certain environments when this gene-environment
interaction is not recognized and explicitly modeled. We did not
directly assess this, but the continuing difficulty of identifying
specific risk alleles despite established heritability supports the
possibility of important environmental modifiers of genetic risk.
This study has important limitations. As with all GWAS, sample
size is a limitation; a larger sample size improves the statistical
power to detect signals and in the case of polygenic risk scores
reduces statistical noise in the different prediction models,
particularly when applying lower p-value thresholds. We used a
continuous phenotype measure to improve statistical power,
although results were similar with a dichotomized measure (data
not shown). But we did not have information on medication usage
or other treatments for anxiety, and the phenotype may therefore
not be manifest in successfully treated individuals; to the extent
that anxiety treatments are successful, this could reduce power. In
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PLOS ONE | www.plosone.org 6 November 2013 | Volume 8 | Issue 11 | e80326addition, polygenic risk scores such as those applied in this study
assume an additive genetic model without interactions which
might not reflect the underlying genetic architecture of the trait.
Moreover, findings in these cohorts, recruited from health
professionals in the U.S., may not be generalizable to represen-
tative population samples. Lastly, the failed attempt to replicate
the findings from Demirkan et al. may be explained by genetic
effects specific to a particular phenotype of anxiety; this would be
somewhat surprising given the evidence from twin studies
suggesting a common liability across anxiety disorders [4]. Our
results do not conclusively rule out the possibility of many
polymorphisms each with very small effects on anxiety symptoms.
Our study was based on secondary analyses of case-control
sample sets; under the null hypothesis of no genotype-phenotype
association, (i.e., in the present study, the genetic risk score and
anxiety ), there is no bias introduced by case-control sampling even
if the phenotype of interest is a correlate of the original condition
used to define case-control status [41].
Despite these limitations, our study is the largest study to date to
investigate the genetics of phobic anxiety. We took advantage of
repeated measures of phobic anxiety to develop a more stable
phenotype. We considered the research question with three
distinct approaches, each with differing strengths and limitations:
GWAS, polygenic risk scores and candidate gene risk scores.
Results from the three approaches were very similar in that none
provided genetic predictors of phobic anxiety.
Conclusion and Future Research Suggestions
Large scale consortia with a common definition of a symptom-
atic measure of anxiety symptoms, clinical anxiety, or usage of
anxiety associated pharmaceuticals are needed to assess potential
(additive) genetics of anxiety using the common GWAS approach-
es. That said, new approaches may be necessary to identify
powerful genetic predictors of anxiety. Critical next steps include
search for genetic or environmental modifiers of genetic effects;
improved genome imputations (e.g. 1000 genomes); and applica-
tion of information on gene expression and biological pathways to
prioritize a subset of genes for closer analyses and thereby mitigate
the ‘false negative challenge in genome-wide analyses. In
particular, identifying social modifiers of genetic risks might
improve statistical power and help explain the ‘‘missing heritabil-
ity’’ gap between GWAS results and twin-study findings.
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